CME: Improving Outcomes in HER2+ Early Breast Cancer: A Focus on the Adjuvant Setting

Improving Outcomes in HER2+ Early Breast Cancer

Improving Outcomes in HER2+ Early Breast Cancer

Patients with HER2+ early breast cancer are in need of better approaches in the adjuvant setting. Luckily, these options are coming down the pike…

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    With clinical trials showing improvements over the current standard of care for HER2+ early breast cancer, incorporating new data and medications into this treatment paradigm is becoming a top priority. Listen in as Dr. Charles Geyer reviews the emerging approaches to adjuvant therapy in patients with HER2+ early breast cancer.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


    Charles E. Geyer, Jr., MD
    Associate Director of Clinical Research
    Virginia Commonwealth Massey Cancer Center
    Richmond, VA

    Financial Disclosure:

    Dr. Geyer has disclosed he receives contracted research from Genentech/Roche.

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Nick Lombardi has ownership interest in Vertex Pharmacueticals.
    • Brian McDonough, MD, FAAFP has nothing to disclose.
    • William A. Mencia, MD has nothing to disclose.
    • Madison Tamburini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Recognize current challenges in the adjuvant treatment of HER2+ EBC
    • Evaluate latest evidence on targeted agents versus standard therapy in the HER2+ EBC adjuvant setting.
    • Identify HER2+ EBC patients that will benefit from recent evidence in the adjuvant setting.
  • Target Audience

    This activity is designed to meet the educational needs of oncologists and list out all the target audiences listed in the grant.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Genentech, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free